Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AUPH Stock Forecast 2026-2027
$14.85
Current Price
$1.96B
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to AUPH Price Targets
+41.4%
To High Target of $21.00
+11.1%
To Median Target of $16.50
-12.5%
To Low Target of $13.00
AUPH Price Momentum
-2.8%
1 Week Change
-8.2%
1 Month Change
+85.4%
1 Year Change
-6.9%
Year-to-Date Change
-10.2%
From 52W High of $16.54
+126.7%
From 52W Low of $6.55
📊 TOP ANALYST CALLS
Did AUPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aurinia is one of their latest high-conviction picks.
Latest AUPH Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, AUPH has a bullish consensus with a median price target of $16.50 (ranging from $13.00 to $21.00). The overall analyst rating is N/A (N/A/10). Currently trading at $14.85, the median forecast implies a 11.1% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Maury Raycroft at Jefferies, projecting a 41.4% upside. Conversely, the most conservative target is provided by Ed Arce at HC Wainwright & Co., suggesting a 12.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AUPH Analyst Ratings
4
Buy
3
Hold
0
Sell
AUPH Price Target Range
Low
$13.00
Average
$16.50
High
$21.00
Current: $14.85
Latest AUPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AUPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $16.00 |
| Nov 7, 2025 | Jefferies | Maury Raycroft | Buy | Upgrade | $21.00 |
| Nov 5, 2025 | RBC Capital | Douglas Miehm | Sector Perform | Downgrade | $15.00 |
| Aug 1, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $9.00 |
| Jul 30, 2025 | HC Wainwright & Co. | Arthur He | Buy | Assumes | $17.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $10.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $10.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Mar 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Feb 23, 2024 | Cantor Fitzgerald | Olivia Brayer | Overweight | Maintains | $10.00 |
| Feb 22, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $13.00 |
| Feb 16, 2024 | RBC Capital | Douglas Miehm | Outperform | Maintains | $8.00 |
| Sep 22, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $15.00 |
| Aug 7, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $15.00 |
| Aug 7, 2023 | HC Wainwright& Co. | Buy | Maintains | $N/A | |
| Jul 6, 2023 | Cantor Fitzgerald | Olivia Brayer | Overweight | Reiterates | $15.00 |
| May 3, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $14.00 |
| Feb 23, 2023 | RBC Capital | Douglas Miehm | Outperform | Reiterates | $11.00 |
| Jan 4, 2023 | RBC Capital | Douglas Miehm | Outperform | Maintains | $11.00 |
| Nov 7, 2022 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $14.00 |
Aurinia Pharmaceuticals Inc. (AUPH) Competitors
The following stocks are similar to Aurinia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aurinia Pharmaceuticals Inc. (AUPH) Financial Data
Aurinia Pharmaceuticals Inc. has a market capitalization of $1.96B with a P/E ratio of 26.5x. The company generates $265.81M in trailing twelve-month revenue with a 29.3% profit margin.
Revenue growth is +8.4% quarter-over-quarter, while maintaining an operating margin of +40.5% and return on equity of +20.7%.
Valuation Metrics
Market Cap
$1.96B
Enterprise Value
$1.68B
P/E Ratio
26.5x
PEG Ratio
0.2x
Price/Sales
7.4x
Growth & Margins
Revenue Growth (YoY)
+8.4%
Gross Margin
+88.9%
Operating Margin
+40.5%
Net Margin
+29.3%
EPS Growth
+119.9%
Financial Health
Cash/Price Ratio
+18.0%
Current Ratio
5.8x
Debt/Equity
21.4x
ROE
+20.7%
ROA
+9.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aurinia Pharmaceuticals Inc. (AUPH) Business Model
About Aurinia Pharmaceuticals Inc.
What They Do
Develops therapies for autoimmune diseases.
Business Model
Aurinia Pharmaceuticals operates by advancing and commercializing innovative therapies specifically targeting autoimmune conditions, with a focus on nephrology. The company generates revenue primarily through the sale of its flagship product for lupus nephritis and aims to expand its portfolio by addressing unmet medical needs in immune system disorders.
Additional Information
Aurinia's commitment to research and development emphasizes personalized medicine and targeted therapies, positioning it as a significant contributor to advancements in the biotech industry. The company aims to improve treatment options for patients suffering from debilitating autoimmune diseases, thus playing a vital role in global healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
130
CEO
Mr. Peter S. Greenleaf M.B.A.
Country
Canada
IPO Year
2014
Website
www.auriniapharma.comAurinia Pharmaceuticals Inc. (AUPH) Latest News & Analysis
Latest News
Quick Summary
Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have been evaluated on their performance relative to their sector in 2023. Further details on their specific performance were not provided.
Why It Matters
Performance comparisons reveal relative strength or weakness, influencing investor sentiment and potential investment decisions in Aurinia Pharmaceuticals and Cardinal Health.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have shown performance metrics relative to their sector in 2023. Further details on performance specifics were not provided.
Why It Matters
The performance comparison of Aurinia Pharmaceuticals and Cardinal Health to their sector indicates potential investment opportunities or risks, influencing portfolio strategies and stock valuations.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Aurinia Pharmaceuticals (AUPH) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to determine its suitability.
Why It Matters
Aurinia Pharmaceuticals' potential as a top stock pick indicates growing interest, which could drive share prices up and attract momentum investors seeking profitable opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
1 month ago
Quick Summary
Tang Capital Management increased its AUPH holdings by 1.3 million shares in Q3, now owning over 11.3 million shares valued at $125.2 million.
Why It Matters
Tang Capital's increased stake in AUPH signals confidence in the company's future, potentially influencing market perception and attracting additional investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have shown performance metrics against their respective sectors in 2023. Further details on specific performance are not provided.
Why It Matters
Performance comparisons highlight how AUPH and CAH are faring against their peers, affecting investor sentiment and potential stock valuation adjustments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Aurinia Pharmaceuticals (AUPH) shares are rising, with positive earnings estimate revisions suggesting potential for continued growth in the near term.
Why It Matters
Aurinia Pharmaceuticals' rising share price and positive earnings estimate revisions signal potential growth, attracting investor interest and possibly enhancing stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About AUPH Stock
What is Aurinia Pharmaceuticals Inc.'s (AUPH) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Aurinia Pharmaceuticals Inc. (AUPH) has a median price target of $16.50. The highest price target is $21.00 and the lowest is $13.00.
Is AUPH stock a good investment in 2026?
According to current analyst ratings, AUPH has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AUPH stock?
Wall Street analysts predict AUPH stock could reach $16.50 in the next 12 months. This represents a 11.1% increase from the current price of $14.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aurinia Pharmaceuticals Inc.'s business model?
Aurinia Pharmaceuticals operates by advancing and commercializing innovative therapies specifically targeting autoimmune conditions, with a focus on nephrology. The company generates revenue primarily through the sale of its flagship product for lupus nephritis and aims to expand its portfolio by addressing unmet medical needs in immune system disorders.
What is the highest forecasted price for AUPH Aurinia Pharmaceuticals Inc.?
The highest price target for AUPH is $21.00 from Maury Raycroft at Jefferies, which represents a 41.4% increase from the current price of $14.85.
What is the lowest forecasted price for AUPH Aurinia Pharmaceuticals Inc.?
The lowest price target for AUPH is $13.00 from Ed Arce at HC Wainwright & Co., which represents a -12.5% decrease from the current price of $14.85.
What is the overall AUPH consensus from analysts for Aurinia Pharmaceuticals Inc.?
The overall analyst consensus for AUPH is bullish. Out of 9 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $16.50.
How accurate are AUPH stock price projections?
Stock price projections, including those for Aurinia Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 2:13 AM UTC